InocuJect Team

Norman Viner

Co-Founder & CEO

Dr. Norman Viner is an early-stage investor, inventor, medical practitioner, consultant and CEO, Co-Founder of InocuJect Corporation. In November 2020, he was asked to help bring a new vaccine device technology to market developed by Dr. Gary Kobinger.

Dr. Viner was the former Chief of the Clinical Trials Division, Biologic and Genetic Therapies Directorate, Health Canada for 15 years. Dr. Viner represented Health Canada on the International Committee for Harmonization (ICH) in rewriting the new Good Clinical Practice (GCP) Guideline - E6R2. He continues to help and invest in academic researchers as well as early-stage companies working on exponential innovative technologies. Dr. Viner graduated from the University of Ottawa Medical School in 1981 and was in full time general practice in the Ottawa area for over 18 years.

Ales Alajbegovic

Co-Founder & COO

Ales is an engineer that led the development & deployment of multiple simulation tools and solutions that are used in the design of almost every vehicle on the road today. Among other roles, he led an expert team of several hundred engineers, responsible for the go-to-market activities of the SIMULIA brand at Dassault Systèmes.

Currently he is the product manager for Teamcenter at Siemens, the world #1 Product Lifecycle Management (PLM) software. This product is used by thousands of companies to enable the next generation of design and manufacturing of their products.

Ed Tate

Co-Founder & Product Development Advisor

Dr. Edward Tate is an experienced executive and prolific inventor with more than 40 patents. He started his career working on General Motors’ first modern electric vehicle, the EV1 where he focused on batteries and powertrain controls. His last vehicle program was the Motor Trend car of the year, the Chevy Volt. In 2012 he joined Exa Corporation, eventually leading the global application management team for ground transportation. In that role, his team worked with major OEMs developing simulation solutions that greatly accelerated product development and dramatically reduced costs. When Exa was acquired by Dassault Systèmes, he led the simulation enablement team for all industries including automotive, aerospace and life sciences.

At InocuJect, he is a co-inventor and advises on product development. He is also the co-founder and CTO of Virtus Solis focusing on space based solar and long-distance wireless power transmission. Ed holds a BSEE & BSME from Kettering University, an MSEE from Stanford University, and a PhD in EE:Systems from the University of Michigan.

Andrew Reid

Marketing Lead

Andrew works to create specialized digital marketing experiences for companies looking to cut through the noise and have their message resonate with investors. Prior to founding his company Outlier Marketing in 2020, Andrew led the marketing team at the NEO Exchange for more than five years. Here he helped small-to-large cap companies with investor awareness marketing throughout their process going public, including the exchange’s first Unicorn. He also developed cost-effective marketing campaigns, formed strategic partnerships with industry organizations, and oversaw the development and implementation of the corporate brand and website user experience. He achieved his Bachelor of Arts in Media and Economics from Queen’s University.

Carter Heikkila

Industrial Design Intern

Carter is studying Industrial Design at the University of Washington Carter will graduate in May 2023. He was selected out of a ~54 Industrial design applicants for his Inocuject intern position. He is passionate about creating experiences that impact users and foster inclusion. Carter has been a very valuable team member, contributing innovative designs and insights for virtual prototypes as well as co-ordinating and helping to develop InocuJect’s business storyboard and introductory videos. Carter’s skills include: Graphic Design, Prototyping, Adobe Suite, Rhino/Solidworks, Keyshot Rendering, Digital/Analog Sketching, HTML/CSS.

Maddison Albert

Engineering Intern

Madison is pursuing a Bachelor of Science in Mechanical and Biomedical Engineering at Tufts University. She was selected out of ~250 applicants for her Inocuject internship position. Maddie will graduate in May 2023. Her skills include: CAD Modeling: SolidWorks, 3D Printing, C, R, MATLAB, Arduino, Hand Tools, Machine Shop Skills, General Laboratory Skills, Microsoft Office. She has been a very valuable team member, contributing to InocuJect’s IP. She is a quick study and consistently delivers high quality work in a timely fashion.

Julian Stoller

Engineering Intern

Julian is pursuing an undergraduate degree in Mechanical Engineering from Cornell University and will graduate in June 2024. His skills include CAD, CFD, 3D printing, and the use of hand tools. He joined Inocuject during the Summer of 2023.

Scientific Advisory Board

Gary Kobinger

Co-Founder & Scientific Advisor

Gary Kobinger is a Canadian immunologist and virologist who is currently the director at the Galveston National Laboratory at the University of Texas. He has held previous professorships at Université Laval, the University of Manitoba, and the University of Pennsylvania. Additionally, he was the chief of the Special Pathogens Unit at the National Microbiology Laboratory (NML) of the Public Health Agency of Canada (PHAC) in Winnipeg, Manitoba for 8 years.

Kobinger is known for his critical role in the development of both an effective Ebola vaccine and an Ebola antibody treatment. His work focuses on the development and evaluation of new vaccine platforms and immunological treatments against emerging and re-emerging viruses that are a significant threat to human health.

John Bell

Scientific Advisor

Dr. John Bell, Co-Founder of Jennerex Biotherapeutics and Turnstone Biologics, has multiple virus products in clinical testing. Turnstone Biologics has raised in excess of 160 million dollars, 50 Canadian employees in Canada.

He is a member of the Center for Cancer Therapeutics at The Ottawa Hospital Cancer Center, a Senior Scientist with the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa. He is the Director of the Canadian Oncolytic Virus Consortium supported by a Terry Fox Program Project Grant and is the Scientific Director of BioCanRx, a Network of Centres of Excellence that aims to bring novel immune stimulating therapies to cancer patients across Canada. His research program has focused on the development of novel viral and cell-based therapeutics for the treatment of cancer and infectious diseases. Dr. Bell is a Fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences.

Dr. Bell’s awards include the Robert L Noble Prize for Outstanding Achievements in Cancer Research from the Canadian Cancer Society, the Distinguished Scientist Award from the Canadian Society for Clinical Investigation, the Outstanding Achievements in Cancer Research from the Canadian Cancer Research Alliance, the American Cancer Society and Society of Surgical Oncology Award, the Dr. Chew Wei Memorial Award in Cancer Research from the University of British Columbia, the European Society of Gene Therapy Patient Engagement Award. He is a Fellow of Royal Society of Canada and a Fellow of the Canadian Academy of Health Sciences.

He received his PhD from McMaster University in 1982. In the three years that followed, he trained as a postdoctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England. Dr. Bell began his independent research career at McGill University in 1986 and moved to the University of Ottawa, Department of Medicine, in 1989.

Jeffrey Dover

Scientific Advisor

Dr. Dover has been a consultant to many startups, small, medium and large companies over the years including but not limited to Zeltiq (acquired by Allergan), Kythera (acquired by Allergan), ConBio and Palomar (both acquired by Cynosure) Cutera, Candela, Lumenis, Pfizer, Johnson & Johnson, Allergan, AbbVie, and Bausch and Lomb. He is the author of over 550 scientific publications and he has co-authored and edited over 55 textbooks. He is founding editor of Journal Watch for Dermatology.

Dr. Dover is a co-director of SkinCare Physicians in Chestnut Hill, Massachusetts and is a former Associate Professor of Dermatology at Harvard Medical School, was Chief of Dermatology at the New England Deaconess Hospital for over ten years and also Associate Chairman of Dermatology at Beth Israel Deaconess Medical Center. He is Associate Clinical Professor of Dermatology at Yale University School of Medicine, and Associate Professor of Dermatology at Brown Medical School. Dr. Dover graduated as the silver medalist, Magna cum Laude from the University of Ottawa. His dermatology training was received at the University of Toronto followed by research fellowships at St. John’s Hospital for Diseases of the Skin at the University of London in London, England, and a two-year photomedicine fellowship at Harvard Medical School.

Dr. Dover is past president of the American Society for Lasers in Medicine and Surgery, the American Society for Dermatologic Surgery, and the New England Dermatology Society. He has received many honors including repeated nominations for “teacher of the year” at Harvard Medical School. He received the prestigious Leon Goldman Award, the Ellet Drake Award, and was honored for his work in laser surgery by the Sturge Weber Foundation at its 20th Annual Gala. He has received presidential citations from both the American Society of Lasers in Medicine and Surgery and the American Society for Dermatological Surgery.